February 16, 2006 – Two immunotherapy drugs from Hemispherx were effective at fighting the avian flu virus in lab tests; CytoDyn will begin a Phase III trial of its new HIV/AIDS drug, which lowered the viral load of HIV/AIDS in human studies; Pain Therapeutics and King Pharma agreed with the FDA on a pivotal Phase III trial design for their chronic pain drug, Remoxy; American Pharma Partners received FDA approvals for injected Ceftriaxone, a generic equivalent of Rocephin; Dr. Reddy’s Labs paid 480 million euros to acquire betapharm Group, the fourth-largest generic company in Germany; Biogen Idec continued its climb higher after the FDA allowed Tysabri to restart clinical trials. The Centient Biotech 200™ was up 37 points at 3968.94, a .94% move higher. More details...
